A 45-year-old Chinese male with a 10-year history of moderate-to-severe plaque psoriasis presents to the pharmacy. He has been prescribed SYSA1902, a biosimilar of ustekinumab, dosed at 45 mg subcutaneously at weeks 0, 4, and 16. He is concerned about whether this biosimilar will be as effective as the original ustekinumab he heard about. His medical history includes hypertension controlled with lisinopril and no known drug allergies.

Based on the phase III study comparing SYSA1902 to reference ustekinumab, what can the pharmacist tell the patient about the expected efficacy of SYSA1902 at week 12?

A 52-year-old female with moderate-to-severe plaque psoriasis is starting treatment with SYSA1902. She has a history of seasonal allergic rhinitis and is concerned about potential side effects. She asks the pharmacist about the safety profile of SYSA1902 compared to the original ustekinumab.

What information regarding treatment-emergent adverse events (TEAEs) can the pharmacist provide based on the clinical trial data for SYSA1902?

A 38-year-old pharmacist is reviewing treatment options for a diverse patient population with moderate-to-severe plaque psoriasis. She considers recommending SYSA1902 as a cost-effective alternative to reference ustekinumab but is aware of the clinical trial population limitations.

What limitation of the SYSA1902 clinical trial should the pharmacist consider when applying the study results to a non-Chinese patient population?